For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240530:nRSd3560Qa&default-theme=true
RNS Number : 3560Q Sareum Holdings PLC 30 May 2024
Sareum Holdings plc
("Sareum" or the "Company")
Appointment of Sole Broker
Cambridge, UK, 30 May 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next-generation kinase inhibitors for
autoimmune disease and cancer, announces that Hybridan LLP is now acting as
the Company's sole broker with immediate effect.
- END -
For Further Information:
Sareum Holdings plc 01223 497700
Tim Mitchell, CEO ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser) 020 7409 3494
James Dance / James Bellman
Hybridan LLP (Corporate Broker) 020 3764 2341
Claire Noyce
ICR Consilium (Financial PR) 0203 709 5700
Jessica Hodgson / Davide Salvi / Kumail Waljee
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END APPVKLFLZELEBBZ